Holen Sie sich die Stockscreener-App
7.825
0.63%
-0.065
Schlusskurs vom Vortag:
$7.89
Offen:
$7.94
24-Stunden-Volumen:
476.31K
Relative Volume:
0.21
Marktkapitalisierung:
$571.16M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-1.6756
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
+6.67%
1M Leistung:
+0.51%
6M Leistung:
-56.78%
1J Leistung:
-73.44%
1-Tages-Spanne:
$7.69
$7.99
1-Wochen-Bereich:
$7.37
$8.05
52-Wochen-Spanne:
$5.90
$30.24
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.825 | 574.44M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.26 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.94 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.42 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.02 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.19 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
What drives Arvinas Inc. stock priceFree Consultation - PrintWeekIndia
How high can Arvinas Inc. stock price go in 2025Skyrocketing investment returns - jammulinksnews.com
What analysts say about Arvinas Inc. stockLightning-fast growth - Autocar Professional
Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat
Arvinas, Inc. (ARVN): A Bull Case Theory - Insider Monkey
Is Arvinas Inc. a good long term investmentRapid growth trajectories - Autocar Professional
Arvinas Inc. Stock Analysis and ForecastPhenomenal trading returns - Autocar Professional
Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment - MSN
Arvinas, Inc. (NASDAQ:ARVN) Receives $20.29 Consensus Price Target from Analysts - MarketBeat
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
(ARVN) Proactive Strategies - news.stocktradersdaily.com
Arvinas (NASDAQ:ARVN) Trading Down 4.6%Here's Why - MarketBeat
Arvinas: A Potential 'Sum Of The Parts' Story (NASDAQ:ARVN) - Seeking Alpha
Arvinas CEO John Houston to retire - MSN
Arvinas stock slides after eliminating trials, reducing workforce - MSN
Arvinas CEO John Houston to retire, remain as board chair By Investing.com - Investing.com South Africa
Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts - MSN
Arvinas (ARVN) Soars 2.62% on CEO Transition - AInvest
Arvinas CEO John Houston to retire, remain as board chair - Investing.com Australia
Gilead signs lenacapavir access deal; Arvinas CEO to step down - BioPharma Dive
Arvinas Announces Retirement of CEO John Houston, Ph.D., - citybiz
Arvinas CEO John Houston to retire after successor is named, will remain board chair - Investing.com Nigeria
Arvinas CEO John Houston to retire after successor is named, will remain board chair By Investing.com - Investing.com South Africa
Arvinas' CEO to Retire; Search for Successor Begins - MarketScreener
Arvinas Announces Retirement of Chief Executive Officer and Succession Plan - The Manila Times
Pioneering Biotech CEO Steps Down: How Arvinas' Houston Transformed Protein Degradation Drug Development - Stock Titan
Arvinas announces board resignation and reports annual meeting voting results By Investing.com - Investing.com South Africa
Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025 - MarketScreener
Arvinas announces board resignation and reports annual meeting voting results - Investing.com
Arvinas, Inc. (NASDAQ:ARVN) CFO Andrew Saik Sells 5,700 Shares - MarketBeat
Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm - TradingView
Arvinas (NASDAQ:ARVN) Shares Gap UpStill a Buy? - MarketBeat
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc - GuruFocus
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.74%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):